Stocks
Immatics N.V.IMTX
NASDAQHealthcareBiotechnology$6.73
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing T-cell receptor (TCR) therapies for solid tumors, with a pipeline focused on PRAME and MAGEA8 targets. Its lead candidate, IMA203, is in Phase 1b/2 trials for melanoma and other cancers, and the company has partnerships with Bristol Myers Squibb and Moderna. Investors track it for its differentiated approach to targeting intracellular cancer antigens and its potential in the growing adoptive cell therapy market.
52W Range: $6.65-$12.41
Congressional Interest in Immatics N.V. (IMTX)
No congressional trades have been disclosed for Immatics N.V. (IMTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading IMTX?
No congressional trades found for this stock.